106 related articles for article (PubMed ID: 19126407)
1. Decrease of dynamin 2 levels in late-onset Alzheimer's disease alters Abeta metabolism.
Kamagata E; Kudo T; Kimura R; Tanimukai H; Morihara T; Sadik MG; Kamino K; Takeda M
Biochem Biophys Res Commun; 2009 Feb; 379(3):691-5. PubMed ID: 19126407
[TBL] [Abstract][Full Text] [Related]
2. Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein.
Harris B; Pereira I; Parkin E
Brain Res; 2009 Nov; 1296():203-15. PubMed ID: 19679113
[TBL] [Abstract][Full Text] [Related]
3. Amyloid precursor protein mRNA levels in Alzheimer's disease brain.
Preece P; Virley DJ; Costandi M; Coombes R; Moss SJ; Mudge AW; Jazin E; Cairns NJ
Brain Res Mol Brain Res; 2004 Mar; 122(1):1-9. PubMed ID: 14992810
[TBL] [Abstract][Full Text] [Related]
4. Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease.
Sahlin C; Pettersson FE; Nilsson LN; Lannfelt L; Johansson AS
Eur J Neurosci; 2007 Aug; 26(4):882-9. PubMed ID: 17714184
[TBL] [Abstract][Full Text] [Related]
5. The intracellular domain of amyloid precursor protein interacts with flotillin-1, a lipid raft protein.
Chen TY; Liu PH; Ruan CT; Chiu L; Kung FL
Biochem Biophys Res Commun; 2006 Mar; 342(1):266-72. PubMed ID: 16480949
[TBL] [Abstract][Full Text] [Related]
6. Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene.
Wang PL; Niidome T; Akaike A; Kihara T; Sugimoto H
J Neurosci Res; 2009 Jul; 87(9):2105-14. PubMed ID: 19267423
[TBL] [Abstract][Full Text] [Related]
7. [Genetic risk factor of Alzheimer's disease].
Kuwano R
Rinsho Shinkeigaku; 2007 Nov; 47(11):908-11. PubMed ID: 18210832
[TBL] [Abstract][Full Text] [Related]
8. Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.
Fernandez-Echevarria C; Díaz M; Ferrer I; Canerina-Amaro A; Marin R
Neuroscience; 2014 Oct; 278():354-66. PubMed ID: 25168729
[TBL] [Abstract][Full Text] [Related]
9. [Lipid rafts, flotillin-1 and Alzheimer disease].
Girardot N; Allinquant B; Duyckaerts C
J Soc Biol; 2003; 197(3):223-9. PubMed ID: 14708344
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting gene expression of alpha3 nicotinic receptor in SH-SY5Y cells with the effects on APP metabolism and antioxidation in Alzheimer's disease.
Tang Z; An Y; Qi XL; Xiao Y; Shan KR; Guan ZZ
Neurochem Int; 2008 Nov; 53(5):112-7. PubMed ID: 18647633
[TBL] [Abstract][Full Text] [Related]
11. Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for beta-amyloid precursor protein and ubiquitin B.
Gerez L; de Haan A; Hol EM; Fischer DF; van Leeuwen FW; van Steeg H; Benne R
Neurobiol Aging; 2005 Feb; 26(2):145-55. PubMed ID: 15582744
[TBL] [Abstract][Full Text] [Related]
12. IGF-1 promotes beta-amyloid production by a secretase-independent mechanism.
Araki W; Kume H; Oda A; Tamaoka A; Kametani F
Biochem Biophys Res Commun; 2009 Feb; 380(1):111-4. PubMed ID: 19167357
[TBL] [Abstract][Full Text] [Related]
13. MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease.
Baig S; Kehoe PG; Love S
Neuropathol Appl Neurobiol; 2008 Apr; 34(2):205-15. PubMed ID: 17971072
[TBL] [Abstract][Full Text] [Related]
14. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease.
Filippini N; Rao A; Wetten S; Gibson RA; Borrie M; Guzman D; Kertesz A; Loy-English I; Williams J; Nichols T; Whitcher B; Matthews PM
Neuroimage; 2009 Feb; 44(3):724-8. PubMed ID: 19013250
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques.
Wozniak MA; Mee AP; Itzhaki RF
J Pathol; 2009 Jan; 217(1):131-8. PubMed ID: 18973185
[TBL] [Abstract][Full Text] [Related]
16. Critical role of methionine-722 in the stimulation of human brain G-proteins and neurotoxicity induced by London familial Alzheimer's disease (FAD) mutated V717G-APP(714-723).
Reis K; Zharkovsky A; Bogdanovic N; Karelson E; Land T
Neuroscience; 2007 Jan; 144(2):571-8. PubMed ID: 17101228
[TBL] [Abstract][Full Text] [Related]
17. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
18. Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex.
Gylys KH; Fein JA; Yang F; Miller CA; Cole GM
Neurobiol Aging; 2007 Jan; 28(1):8-17. PubMed ID: 16332401
[TBL] [Abstract][Full Text] [Related]
19. A mutation screening by DHPLC of PSEN1 and APP genes reveals no significant variation associated with the sporadic late-onset form of Alzheimer's disease.
Scacchi R; Gambina G; Moretto G; Corbo RM
Neurosci Lett; 2007 May; 418(3):282-5. PubMed ID: 17412506
[TBL] [Abstract][Full Text] [Related]
20. Dynamin 2 gene is a novel susceptibility gene for late-onset Alzheimer disease in non-APOE-epsilon4 carriers.
Aidaralieva NJ; Kamino K; Kimura R; Yamamoto M; Morihara T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Kida T; Okuda JI; Uema T; Yamagata H; Miki T; Akatsu H; Kosaka K; Takeda M
J Hum Genet; 2008; 53(4):296-302. PubMed ID: 18236001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
